PLCB3

PLCB3 is a ubiquitously expressed phosphoinositide-specific phospholipase C that hydrolyzes PIP2 to generate IP3 and DAG downstream of heterotrimeric G proteins coupled to GPCRs and immune receptors, thereby controlling intracellular calcium mobilization, PKC activation, and NF-κB signaling across diverse cell types (PMID:7607669, PMID:21411730, PMID:29668297). In mast cells, PLCB3 functions as a scaffold that constitutively associates with FcεRI, Lyn, and SHP-1; upon receptor activation it recruits SHP-1 to dephosphorylate Lyn, tuning MAPK-dependent cytokine production and STAT5-driven mast cell expansion, such that Plcb3 deficiency causes spontaneous atopic dermatitis–like disease (PMID:21683628, PMID:24412367). Ser1105 serves as a convergent phosphorylation node for PKA and PKC, with differential dephosphorylation by calcineurin versus PP1/PP2A enabling cross-talk between cAMP and Gq pathways in myometrial cells (PMID:18322273). A homozygous destabilizing missense variant (p.Ala878Ser) causes elevated PIP2, F-actin disorganization, and spondylometaphyseal dysplasia with corneal dystrophy, while PLCB3 protein stability is maintained by OSBPL2-mediated protection from ubiquitin-dependent degradation (PMID:29122926, PMID:38701954).

1. 1995 High

   Establishing the basic identity of PLCB3 as a ubiquitously expressed, housekeeping-type phospholipase C gene answered the foundational question of its genomic organization and tissue distribution.

   Evidence cDNA/genomic sequencing, Northern blotting, and primer extension in human tissues

   PMID:7607669

   Open questions at the time

   • No enzymatic kinetics or substrate specificity data provided
   • No upstream activating receptors identified
   • Protein-level expression and subcellular localization not characterized
2. 1999 Medium

   Reconstitution of PLCB3 in neuroendocrine tumor cells deficient for the protein revealed a growth-suppressive function, raising the question of whether PLCB3 acts as a tumor suppressor beyond its canonical lipase activity.

   Evidence PLCB3 cDNA transfection with thymidine incorporation assays and nude mouse xenografts

   PMID:10359076

   Open questions at the time

   • Mechanism of growth suppression not defined
   • Downstream transcriptional changes identified by differential display (PMID:11178984) lack validation
   • Relevance to human neuroendocrine tumors in situ not established
3. 2006 Medium

   Demonstrating that intracellular PLCB3-specific antibody blocked S1P-induced smooth muscle contraction placed PLCB3 downstream of both Gi and Gq pathways and upstream of PKCε/MEK/ERK in a contractile signaling cascade.

   Evidence Intracellular antibody injection in permeabilized cat esophageal smooth muscle cells with pertussis toxin and kinase inhibitors

   PMID:16511346

   Open questions at the time

   • Antibody specificity for PLCB3 versus other PLC isoforms not independently validated
   • Single species/tissue system
   • Direct G-protein coupling not biochemically demonstrated
4. 2008 High

   Identification of Ser1105 as a convergent PKA/PKC phosphorylation site with differential phosphatase control resolved how cAMP and Gq/oxytocin pathways cross-talk through PLCB3 in myometrial cells.

   Evidence S1105A mutagenesis, shRNA knockdown, pharmacological phosphatase and kinase inhibition, calcium imaging in human myometrial cells

   PMID:18322273

   Open questions at the time

   • Structural basis for how S1105 phosphorylation inhibits catalytic activity unknown
   • In vivo relevance to labor/uterine contractility not tested
   • Whether other PLC-β isoforms are similarly regulated at homologous sites not addressed
5. 2011 High

   Discovery that PLCB3 constitutively scaffolds FcεRI, Lyn, and SHP-1 in mast cells — and that Plcb3 knockout phenocopies SHP-1 loss for cytokine production — established a non-canonical adaptor/scaffold function independent of lipase activity per se.

   Evidence Plcb3−/− mouse, reciprocal co-immunoprecipitation, Lyn kinase assays, anaphylaxis models, cytokine ELISA

   PMID:21683628

   Open questions at the time

   • Whether the scaffold and lipase functions are separable (e.g., catalytic-dead knock-in) was not tested
   • Structural basis for the quaternary PLCB3–FcεRI–Lyn–SHP-1 complex unknown
   • Contribution of individual PLCB3 domains to complex assembly not mapped
6. 2011 High

   Parallel work showed PLCB3 mediates nucleotide-stimulated Ca²⁺/PKC/NF-κB signaling that potentiates TLR-driven IL-8 release in bronchial epithelial cells, extending its functional role to innate immune amplification in the airway.

   Evidence siRNA knockdown in CF bronchial epithelial cells with calcium, PKC, NF-κB reporter, and IL-8 readouts

   PMID:21411730

   Open questions at the time

   • Receptor identity (P2Y subtype) upstream of PLCB3 not definitively assigned
   • In vivo relevance in CF lung disease not tested
7. 2014 High

   Epistasis experiments in Plcb3-deficient mice showed that PLCB3 restrains STAT5 activity via SHP-1, and that mast cell-specific Stat5 deletion rescues dermatitis, establishing the PLCB3→SHP-1⊣STAT5 axis as the driver of mast cell expansion and atopic skin disease.

   Evidence Plcb3−/− crossed with mast cell-specific Stat5 and Shp1 conditional knockouts, allergen challenge

   PMID:24412367

   Open questions at the time

   • How PLCB3 regulates periostin in fibroblasts and TSLP in keratinocytes mechanistically unclear
   • Whether lipase activity is required for the STAT5 regulatory circuit not resolved
8. 2017 High

   Identification of a homozygous destabilizing PLCB3 variant (p.Ala878Ser) in patients with spondylometaphyseal dysplasia with corneal dystrophy demonstrated that PLCB3 loss-of-function elevates PIP2, disrupts F-actin, and causes a Mendelian skeletal syndrome.

   Evidence Whole exome sequencing, homozygosity mapping, PIP2 measurement and F-actin staining in patient fibroblasts

   PMID:29122926

   Open questions at the time

   • No animal model recapitulating the skeletal phenotype
   • How elevated PIP2 specifically leads to chondrocyte/corneal pathology not defined
   • Whether residual enzymatic activity exists with the A878S variant not quantified
9. 2018 High

   Systematic active-site mutagenesis confirmed that PLCB3 catalytic activity is required for agonist-induced Ca²⁺ release, PKCβ activation, and IL-8 production, ruling out a purely scaffold-based mechanism in epithelial innate immunity.

   Evidence Catalytic-dead and activation-deficient mutants with Ca²⁺ imaging, PKC and IL-8 assays in CF bronchial epithelial cells

   PMID:29668297

   Open questions at the time

   • S845L variant structural consequences not resolved crystallographically
   • Whether scaffold and catalytic functions both contribute in mast cells remains untested
10. 2024 Medium

    Discovery that OSBPL2 directly binds and protects PLCB3 from ubiquitin-dependent proteasomal degradation revealed a post-translational stability mechanism, explaining how OSBPL2 loss-of-function causes keratinocyte hyperkeratosis via PLCB3 depletion.

    Evidence Reciprocal co-immunoprecipitation, ubiquitylation assays, patient fibroblast/keratinocyte studies

    PMID:38701954

    Open questions at the time

    • E3 ubiquitin ligase targeting PLCB3 not identified
    • Ubiquitylation sites on PLCB3 not mapped
    • Whether OSBPL2 regulation of PLCB3 is relevant in non-epidermal tissues unknown

• Key unresolved questions include whether the scaffold and lipase functions of PLCB3 are separable in vivo, the identity of the E3 ligase controlling PLCB3 turnover, the structural basis for Ser1105 phospho-regulation, and the mechanism by which PIP2 accumulation drives skeletal dysplasia.
• No catalytic-dead knock-in mouse to dissect scaffold versus enzymatic roles
• E3 ligase for PLCB3 ubiquitylation unknown
• No high-resolution structure of full-length PLCB3 in a signaling complex